Related Experiment Video
Updated: Jun 24, 2026
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
Semaphorin3A immunohistochemical expression in human meningiomas: correlation with the microvessel density
Valeria Barresi1, Enrica Vitarelli, Serenella Cerasoli
1Department of Human Pathology, University of Messina, Messina, Italy. vbarresi@unime.it
Abstract:
The immunoexpression of the antiangiogenic factor semaphorin3A (SEMA3A) was evaluated in a series of meningiomas. Then, its correlations with the microvessel density (MVD) of the tumors and with the clinicopathological parameters as well with the survival time or recurrence-free interval were investigated. A positive SEMA3A immunostaining was found in most of meningiomas and a significant association was found between a high expression of this protein and a low MVD of the tumors. Moreover, a low SEMA3A immunoexpression was significantly correlated with a higher recurrence rate of meningiomas. In conclusion, our findings suggest a role for SEMA3A as an antiangiogenic factor in meningiomas with its decrease being associated with the development of recurrences. The supplementation of SEMA3A might be used in novel therapeutic antiangiogenic strategies to prevent the recurrence of highly vascularized meningiomas.
Insights
Semaphorin3A (SEMA3A) acts as an antiangiogenic factor in meningiomas. Lower SEMA3A expression correlates with increased tumor recurrence, suggesting therapeutic potential.
Area of Science:
- Neuro-oncology
- Tumor Angiogenesis
- Molecular Pathology
Background:
- Meningiomas are the most common primary intracranial tumors.
- Tumor angiogenesis plays a critical role in meningioma progression.
- The role of semaphorin3A (SEMA3A) in meningioma pathogenesis is not well understood.
Purpose of the Study:
- To investigate the immunoexpression of SEMA3A in meningiomas.
- To correlate SEMA3A expression with tumor microvessel density (MVD).
- To examine the relationship between SEMA3A expression and clinicopathological parameters, including recurrence and survival.
Main Methods:
- Immunohistochemical analysis of SEMA3A expression in a cohort of meningioma samples.
- Quantification of microvessel density (MVD) using established methods.
- Statistical analysis to assess correlations between SEMA3A expression, MVD, and clinical outcomes.
Main Results:
- Positive SEMA3A immunostaining was observed in the majority of meningiomas.
- High SEMA3A expression was significantly associated with lower MVD.
- Low SEMA3A immunoexpression correlated significantly with a higher rate of meningioma recurrence.
Conclusions:
- SEMA3A functions as an antiangiogenic factor in meningiomas.
- Decreased SEMA3A expression is linked to meningioma recurrence.
- Targeting SEMA3A could offer novel antiangiogenic therapeutic strategies for preventing recurrence in highly vascularized meningiomas.
